235 related articles for article (PubMed ID: 34881389)
21. From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity.
Ederhy S; Devos P; Cohen A; Pinna B; Bretagne M; Nguyen LS; Salem JE
Therapie; 2022; 77(2):197-206. PubMed ID: 34895759
[TBL] [Abstract][Full Text] [Related]
22. Cardio-oncology: Understanding cardiotoxicity to guide patient focused imaging.
Russell R
J Nucl Cardiol; 2018 Dec; 25(6):2159-2167. PubMed ID: 30443750
[TBL] [Abstract][Full Text] [Related]
23. Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.
Butel-Simoes LE; Haw TJ; Williams T; Sritharan S; Gadre P; Herrmann SM; Herrmann J; Ngo DTM; Sverdlov AL
Hypertension; 2023 Apr; 80(4):685-710. PubMed ID: 36756872
[TBL] [Abstract][Full Text] [Related]
24. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment.
Yegya-Raman N; Berlin E; Feigenberg SJ; Ky B; Sun L
Curr Oncol Rep; 2023 May; 25(5):433-444. PubMed ID: 36811807
[TBL] [Abstract][Full Text] [Related]
26. Cardiotoxicity: anthracyclines and long term cancer survivors.
Patanè S
Int J Cardiol; 2014 Oct; 176(3):1326-8. PubMed ID: 25129289
[No Abstract] [Full Text] [Related]
27. [Cardiotoxicity of Cancer Chemotherapy - Mechanisms and Therapeutic Approach].
Akazawa H
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2058-2063. PubMed ID: 29361617
[TBL] [Abstract][Full Text] [Related]
28. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: possible implications in cancer patients with COVID-19.
Quagliariello V; Paccone A; Iovine M; Cavalcanti E; Berretta M; Maurea C; Canale ML; Maurea N
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6797-6812. PubMed ID: 34787884
[TBL] [Abstract][Full Text] [Related]
30. Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology.
Liang Z; He Y; Hu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142538
[TBL] [Abstract][Full Text] [Related]
31. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Corremans R; Adão R; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):204-215. PubMed ID: 30244497
[TBL] [Abstract][Full Text] [Related]
32. Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients.
Ryan TD; Nagarajan R; Godown J
Curr Treat Options Oncol; 2019 May; 20(7):56. PubMed ID: 31129800
[TBL] [Abstract][Full Text] [Related]
33. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.
Caspani F; Tralongo AC; Campiotti L; Asteggiano R; Guasti L; Squizzato A
Intern Emerg Med; 2021 Mar; 16(2):477-486. PubMed ID: 33011930
[TBL] [Abstract][Full Text] [Related]
34. [Management of cardiovascular complications secondary to medical treatment of cancer].
Banke A; Polk A; Nielsen D; Videbæk L; Overgaard U; Fosbøl EL; Vaage-Nielsen M; Nielsen KM; Schou M
Ugeskr Laeger; 2018 Feb; 180(7):. PubMed ID: 29465031
[TBL] [Abstract][Full Text] [Related]
35. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM
Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560
[TBL] [Abstract][Full Text] [Related]
36. Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention.
Narayan V; Ky B
Annu Rev Med; 2018 Jan; 69():97-111. PubMed ID: 29414258
[TBL] [Abstract][Full Text] [Related]
37. Use of new and emerging cancer drugs: what the cardiologist needs to know.
Fabiani I; Chianca M; Aimo A; Emdin M; Dent S; Fedele A; Cipolla CM; Cardinale DM
Eur Heart J; 2024 Jun; 45(22):1971-1987. PubMed ID: 38591670
[TBL] [Abstract][Full Text] [Related]
38. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
39. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
40. Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review.
Serini S; Ottes Vasconcelos R; Nascimento Gomes R; Calviello G
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29231904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
